Sarepta silent on FDA's riposte

Sarepta Therapeutics Inc. (NASDAQ:SRPT) declined to comment on Friday after FDA vigorously defended itself in front of the Duchenne muscular dystrophy (DMD) community over the agency's advice and treatment of the company's eteplirsen ( AVI-4658). In a rare (see BioCentury Extra, Oct. 27).

In its Thursday statement, FDA said its "most recent advice was consistent with the advice provided" following an April meeting with Sarepta. ...